Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant: Leadership Award for Vaccine Res. - CEPI-CIHR

McMaster University

$300,000.00

Development and characterization of a broadly-protective mucosal vaccine for highly-pathogenic avian influenza H5N1

FY 2025-26

Summary
Influenza viruses have caused multiple global pandemics over the past century and continue to pose a serious threat to human health. Highly pathogenic avian influenza (H5N1), has recently spread widely in birds and other animals. Since 2024, it also been detected in dairy cattle in the U.S. This virus has caused human infections in both the United States and Canada, raising concerns about its pandemic potential. Current influenza vaccines are given by injection and fail to generate strong immune responses in the lungs, where severe influenza causes the most damage. They also tend to work best only against closely matched strains, limiting their usefulness against new, emerging viruses like H5N1. Our team has developed a new type of vaccine that is delivered directly to the airways. This approach is designed to build strong immunity in the lungs-the main site of serious influenza disease-and to provide broader, longer-lasting protection. We have already shown that this vaccine platform works well against COVID-19 and is safe in people. In this project, we will adapt this technology to create a next-generation vaccine against H5N1 influenza. We will test whether this vaccine can safely trigger strong immune defenses in the lungs, protect against severe disease, and defend against different strains of influenza in animal models. We will also study how the vaccine works, including the roles of antibodies, immune cells, and the body's early "first-line" defenses. This research aims to lay the groundwork for a more effective, broadly protective influenza vaccine to help Canada and the world prepare for future influenza pandemics.
Program
Operating Grant: Leadership Award for Vaccine Res. - CEPI-CIHR
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
571350
Name
Miller Matthew S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Operating Grant: Leadership Award for Vaccine Research
Projecttitle
Development and characterization of a broadly-protective mucosal vaccine for highly-pathogenic avian influenza H5N1
Programtype2
Operating Grants
Orgnameinp2
McMaster University
Cihramount2
$300,000
Cihrequipment2
$0
Programname2
Operating Grant: Leadership Award for Vaccine Res. - CEPI-CIHR
Keyworddelim
Avian Influenza; Mucosal Vaccine
Abstract
Influenza viruses have caused multiple global pandemics over the past century and continue to pose a serious threat to human health. Highly pathogenic avian influenza (H5N1), has recently spread widely in birds and other animals. Since 2024, it also been detected in dairy cattle in the U.S. This virus has caused human infections in both the United States and Canada, raising concerns about its pandemic potential. Current influenza vaccines are given by injection and fail to generate strong immune responses in the lungs, where severe influenza causes the most damage. They also tend to work best only against closely matched strains, limiting their usefulness against new, emerging viruses like H5N1. Our team has developed a new type of vaccine that is delivered directly to the airways. This approach is designed to build strong immunity in the lungs-the main site of serious influenza disease-and to provide broader, longer-lasting protection. We have already shown that this vaccine platform works well against COVID-19 and is safe in people. In this project, we will adapt this technology to create a next-generation vaccine against H5N1 influenza. We will test whether this vaccine can safely trigger strong immune defenses in the lungs, protect against severe disease, and defend against different strains of influenza in animal models. We will also study how the vaccine works, including the roles of antibodies, immune cells, and the body's early "first-line" defenses. This research aims to lay the groundwork for a more effective, broadly protective influenza vaccine to help Canada and the world prepare for future influenza pandemics.
Competitiondate
202602
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Miller, Matthew S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $300,000~ $0~